New Pill Doubles Pancreatic Cancer Survival
A groundbreaking new pill, daraxonrasib, has demonstrated remarkable success in clinical trials for metastatic pancreatic cancer, effectively doubling patients' median survival time from 6.7 to 13.2 months. This significant breakthrough offers renewed hope by targeting specific cancer cell pathways, providing a much-needed therapeutic option for a previously intractable disease.